Labcorp (LH) Launches Marker Genetic Health Panel For Consumer Testing
Labcorp Holdings Inc LH
$309.20
▼ -2.01%
($-6.33)
Index member:
S&P 500
Open
$312.35
Prev Close
$315.53
Day Range
$305.06 – $314.83
52W Range
$244.52 – $316.11
Market Cap
$25.35B
P/E (TTM)
26.93
Beta
0.87
Div Yield
0.91%
EPS (TTM)
$11.29
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NEW YORK STOCK EXCHANGE, INC. |
| Currency | USD |
| IPO Date | 1991-04-24 |
| Shares Out. | 82,000,000 |
| Website | labcorp.com/ ↗ |
| Phone | 13362291127 |
| Employees | 71,000 |
| Revenue | $3.54B |
| Gross Profit | $1.01B |
| Net Income | $278.0M |
| Free Cash Flow | $1.38B |
| Total Assets | $19.09B |
| Total Liabilities | $10.34B |
| Equity | $8.75B |
About Labcorp Holdings Inc
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
Labcorp Holdings Inc is a publicly traded company under the ticker symbol LH on the NEW YORK STOCK EXCHANGE, INC., operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
28 analysts (2026-07-01)
📰 Latest News for LH
LH Q2 Deep Dive: Specialty Testing and Consumer Growth Drive Guidance Increase
Is DGX Stock Worth Buying After Its Strong 2026 Earnings Momentum?
Morgan Stanley Maintains Overweight on Labcorp Holdings, Raises Price Target to $338
Labcorp Q2 Earnings Call Highlights
Truist Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $350
Barclays Maintains Equal-Weight on Labcorp Holdings, Raises Price Target to $320
Labcorp Holdings Inc. Q2 2026 Earnings Call Summary